<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FOSCAVIR- foscarnet sodium injection, solution </strong><br>Clinigen Healthcare Ltd.<br></p></div>
<h1>FOSCAVIR <span class="Sup">® </span><br><span class="Italics">(foscarnet sodium)</span> INJECTION
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="s2"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">WARNING</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">RENAL IMPAIRMENT</span> IS THE MAJOR TOXICITY OF FOSCAVIR.  FREQUENT MONITORING OF SERUM CREATININE, WITH DOSE ADJUSTMENT FOR CHANGES IN RENAL FUNCTION, AND ADEQUATE HYDRATION WITH ADMINISTRATION OF FOSCAVIR IS IMPERATIVE.  (See <a href="#s45">ADMINISTRATION section; Hydration.</a>)</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">SEIZURES</span>, RELATED TO ALTERATIONS IN PLASMA MINERALS AND ELECTROLYTES, HAVE BEEN ASSOCIATED WITH FOSCAVIR TREATMENT.  THEREFORE, PATIENTS MUST BE CAREFULLY MONITORED FOR SUCH CHANGES AND THEIR POTENTIAL SEQUELAE. MINERAL AND ELECTROLYTE SUPPLEMENTATION MAY BE REQUIRED.</span></p>
<p><span class="Bold">FOSCAVIR IS INDICATED FOR USE ONLY IN IMMUNOCOMPROMISED PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV RETINITIS</span> AND MUCOCUTANEOUS ACYCLOVIR-RESISTANT HSV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span>.  (See <a href="#s17">INDICATIONS</a> section).</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s3"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First">FOSCAVIR is the brand name for foscarnet sodium. The chemical name of foscarnet sodium is phosphonoformic acid, trisodium salt. Foscarnet sodium is a white, crystalline powder containing 6 equivalents of water of hydration with an empirical formula of Na<span class="Sub">3</span>CO<span class="Sub">5</span>P•<span class="Sub">6</span> H<span class="Sub">2</span>0 and a molecular weight of 300.1. The structural formula is:
</p>
<p><a name="f01"></a><img alt="structural formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a09299d5-9c55-4cef-aed0-3a6a45532289&amp;name=fos01-0004-01.jpg"></p>
<p>FOSCAVIR has the potential to chelate divalent metal ions, such as calcium and magnesium, to form stable coordination compounds. FOSCAVIR INJECTION is a sterile, isotonic aqueous solution for intravenous administration only. The solution is clear and colorless. Each milliliter of FOSCAVIR contains 24 mg of foscarnet sodium hexahydrate in Water for Injection, USP. Hydrochloric acid may have been added to adjust the pH of the solution to 7.4. FOSCAVIR INJECTION contains no preservatives.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-2"></a><p></p>
<h1>VIROLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s5"></a><a name="section-2.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Foscarnet exerts its antiviral activity by a selective inhibition at the pyrophosphate binding site on virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. Foscarnet does not require activation (phosphorylation) by thymidine kinase or other kinases.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-2.2"></a><p></p>
<h2>Antiviral Activity in Cell Culture</h2>
<p class="First">The quantitative relationship between the cell culture susceptibility of human cytomegalovirus (CMV) or herpes simplex virus 1 and 2 (HSV-1 and HSV-2) to foscarnet and clinical response to therapy has not been established and virus sensitivity testing has not been standardized. Sensitivity test results, expressed as the concentration of drug required to inhibit by 50% the growth of virus in cell culture (EC<span class="Sub">50</span>), vary greatly depending on the assay method used, cell type employed and the laboratory performing the test. A number of sensitive viruses and their EC<span class="Sub">50</span> values are listed below (<a href="#t1">Table 1</a>). The combination antiviral activity of foscarnet and ganciclovir or acyclovir are not antagonistic in cell culture.</p>
<a name="t1"></a><table width="100%">
<caption><span>TABLE 1 Foscarnet Inhibition of Virus Replication in Cell Culture
</span></caption>
<col align="left" width="65.350%">
<col align="left" width="34.650%">
<tfoot><tr class="First Last"><td align="left" colspan="2" valign="top"><p class="First Footnote">*Mean = 269 μM
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="justify" valign="top">Virus
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">EC<span class="Sub">50</span> value (μM)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="justify" valign="top">CMV<br>Ganciclovir resistant CMV<br>HSV-1, HSV-2<br>HSV-TK negative mutant<br>HSV-DNA polymerase mutants
</td>
<td class="Botrule Rrule" align="center" valign="top">50-800*<br>190<br>10-130<br>67<br>5-443
</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Antiviral Activity <span class="Italics">in vivo</span></span></p>
<p>Statistically significant decreases in positive CMV cultures from blood and urine have been demonstrated in two studies (FOS-03 and ACTG-015/915) of subjects treated with FOSCAVIR. Although median time to progression of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> was increased in subjects treated with FOSCAVIR, reductions in positive blood or urine cultures have not been shown to correlate with clinical efficacy in individual subjects (<a href="#t2">Table 2</a>).
</p>
<a name="t2"></a><table width="100%">
<caption><span>TABLE 2 Blood and Urine Culture Results from <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span> Patients*
</span></caption>
<col align="left" width="46.950%">
<col align="left" width="10%">
<col align="left" width="26.700%">
<col align="left" width="25.775%">
<tfoot>
<tr class="First"><td align="left" colspan="4" valign="top"><p class="First Footnote">*A total of 77 subjects were treated with FOSCAVIR in two clinical trials (FOS-03 and ACTG-015/915).
</p></td></tr>
<tr><td align="left" colspan="4" valign="top"><p class="First Footnote">Not all subjects had blood or urine cultures done and some subjects had results from both cultures.
</p></td></tr>
<tr class="Last"><td align="left" colspan="4" valign="top"><p class="First Footnote">†(60 mg/kg FOSCAVIR TID for 2–3 weeks).
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="top">Blood
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">+CMV
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">-CMV
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" colspan="2" valign="top">Baseline
</td>
<td class="Rrule" align="center" valign="top">27
</td>
<td class="Rrule" align="center" valign="top">34
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top">End of Induction†
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">60
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top">Urine
</td>
<td class="Botrule Rrule" align="center" valign="top">+CMV
</td>
<td class="Botrule Rrule" align="center" valign="top">-CMV
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" colspan="2" valign="top">Baseline
</td>
<td class="Rrule" align="center" valign="top">52
</td>
<td class="Rrule" align="center" valign="top">6
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left" valign="top">End of Induction†
</td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">21
</td>
<td class="Botrule Rrule" align="center" valign="top">37
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-2.3"></a><p></p>
<h2>Resistance
</h2>
<p class="First">Cell culture: CMV and HSV isolates with reduced susceptibility to foscarnet have been selected in cell culture by passage of wild type virus in the presence of increasing concentrations of the drug. All foscarnet resistant isolates are known to be generated through amino acid substitutions in the viral DNA polymerase pUL54 (CMV) or pUL30 (HSV) (<a href="#t3">Table 3</a>).</p>
<a name="t3"></a><table width="100%">
<caption><span>TABLE 3 Summary of Foscarnet Resistance-associated DNA Polymerase Amino Acid Substitutions in Cell Culture
</span></caption>
<col align="left" width="7%">
<col align="left" width="93%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="top">CMV pUL54
                  </td>
<td class="Botrule Rrule" align="left" valign="top">T419M, T552N, S585A, F595I, Q807A, M844T/V, V946L
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">HSV-1 pUL30
                  </td>
<td class="Botrule Rrule" align="left" valign="top">Y577H, E597D, A605V, L702H, V714M, L774F,  L788M, D780N, L782I, P797T, L802F, V813M, V817M, Y818C, T821M, R842S, S889A, F891C, V892M, D907V, A910V, SRA914-916LCV, V958L, R959H
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">HSV-2 pUL30
                  </td>
<td class="Botrule Rrule" align="left" valign="top">_
</td>
</tr>
</tbody>
</table>
<p><span class="Italics">In vivo</span>: Limited clinical data are available on the development of clinical resistance to foscarnet and many pathways to resistance likely exist. Substitutions documented in the literature in treated patients as associated with foscarnet resistance, are listed in <a href="#t4">Table 4</a>.</p>
<a name="t4"></a><table width="100%">
<caption><span>TABLE 4 Summary of Foscarnet Resistance-associated Amino Acid Substitutions Observed in Treated Patients
</span></caption>
<col align="left" width="7%">
<col align="left" width="93%">
<tfoot><tr class="First Last"><td align="left" colspan="2" valign="top"><p class="First Footnote">Note: Many additional pathways to foscarnet resistance likely exist
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="top">CMV pUL54
                  </td>
<td class="Botrule Rrule" align="left" valign="top">N495K, Q578H/L, D588E/N, T700A, V715M, E756D/K/Q, L773V, L776M, V781I, V787L, L802M, A809V, V812L, T813S, T821I, A834P, T838A, G841A/S, del 981-982
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">HSV-1 pUL30
                  </td>
<td class="Botrule Rrule" align="left" valign="top">S599L, D672N, R700G V715G, A719T/V, S724N, E798K, G841C/S, A910T, Y941H
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">HSV-2 pUL30
                  </td>
<td class="Botrule Rrule" align="left" valign="top">A724T, S725G, S729N, Q732R, L783M, D785N, T844I, L850I, D912V
</td>
</tr>
</tbody>
</table>
<p>The possibility of viral resistance should be considered in patients who show poor clinical response or experience persistent viral excretion during therapy.</p>
<p>Cross-Resistance: The amino acid substitutions that resulted in reduced susceptibility to foscarnet and either ganciclovir, acyclovir and/or cidofovir are summarized in Tables <a href="#t5">5</a> and <a href="#t6">6</a>.</p>
<a name="t5"></a><table width="80%">
<caption><span>TABLE 5 Summary of CMV DNA polymerase Amino Acid Substitutions Conferring Foscarnet Resistance with Cross-Resistance to Ganciclovir and/or Cidofovir
</span></caption>
<col align="left" width="13%">
<col align="left" width="7%">
<col align="left" width="60%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Cross-resistant to ganciclovir</span></td>
<td class="Botrule Lrule Rrule" align="left" valign="top">CMV pUL54
                  </td>
<td class="Botrule Rrule" align="left" valign="top">Q578H, D588N, E756K, L773V, L776M, V781I, V787L, L802M, A809V,V812L, T813S, T821I, A834P, G841A/S, del 981-982 </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Cross-resistant to cidofovir</span></td>
<td class="Botrule Lrule Rrule" align="left" valign="top">CMV pUL54
                  </td>
<td class="Botrule Rrule" align="left" valign="top">Q578H, D588N,E756K, L773V, V812L, T813S, A834P, G841A, del 981-982
</td>
</tr>
</tbody>
</table>
<a name="t6"></a><table width="80%">
<caption><span>TABLE 6 Summary of HSV DNA polymerase Amino Acid Substitutions Conferring Foscarnet Resistance with Cross-Resistance to Acyclovir and/or Cidofovir
</span></caption>
<col width="24%">
<col width="10%">
<col width="67%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top">
<p class="First"><span class="Bold">Cross-resistant to </span></p>
<p><span class="Bold">acyclovir</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">HSV-1 pUL30</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">E597D, S599L, A605V, D672N, R700G, L702H, V714M, V715G, A719T/V, S724N, L774F, L778M, D780N, L782I, P797T, E798K, L802F, V813M, V817M, Y818C, T821M, G841C/S, R842S, S889A, F891C/Y, V892M, D907V, A910V/T, SRA914-916LCV, Y941H, V958L, V959H</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">HSV-2 pUL30</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">A724T, S725G, S729N, Q732R, L783M, D785N, T844I, D912V</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2" valign="top">
<p class="First"><span class="Bold">Marginally </span></p>
<p><span class="Bold">cross-resistant to cidofovir</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">HSV-1 pUL30</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">V714M, A719V, S724N, L778M, L802F, Y818C, T821M, G841S</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">HSV-2 pUL30</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">L783M</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s8"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43682-4">
<a name="s9"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics
</h2>
<p class="First">The pharmacokinetics of foscarnet has been determined after administration as an intermittent intravenous infusion during induction therapy in AIDS patients with <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>. Observed plasma foscarnet concentrations in four studies (FOS-01, ACTG-015, FP48PK, FP49PK) are summarized in <a href="#t7">Table 7</a>:
</p>
<a name="t7"></a><table width="100%">
<caption><span>TABLE 7 Foscarnet Pharmacokinetic Characteristics*
</span></caption>
<col align="left" width="42.800%">
<col align="left" width="28.600%">
<col align="left" width="28.600%">
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"><p class="First Footnote">*Values expressed as mean S.D. (number of subjects studied) for each parameter
</p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote">†50 mg/kg Q8h for 28 days, samples taken 3 hrs after end of 1 hr infusion (Astra Report 815-04 AC025-1)
</p></td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"><p class="First Footnote">‡90 mg/kg Q12hr for 28 days, samples taken 1hr after end of 2 hr infusion (Hengge et al., 1993)
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Parameter</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">60 mg/kg Q8h</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">90 mg/kg Q12h</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">C</span><span class="Sub">max
</span><span class="Bold">at steady-state (μM)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">589 ± 192 (24)
</td>
<td class="Botrule Rrule" align="center" valign="top">623 ± 132 (19)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">C</span><span class="Sub">trough
</span><span class="Bold">at steady-state (μM)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">114 ± 91 (24)
</td>
<td class="Botrule Rrule" align="center" valign="top">63 ± 57 (17)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Volume of distribution (L/kg)</span></td>
<td class="Botrule Rrule" align="center" valign="top">0.41 ± 0.13 (12)
</td>
<td class="Botrule Rrule" align="center" valign="top">0.52 ± 0.20 (18)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Plasma half-life (hr)</span></td>
<td class="Botrule Rrule" align="center" valign="top">4.0 ± 2.0 (24)
</td>
<td class="Botrule Rrule" align="center" valign="top">3.3 ± 1.4 (18)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Systemic clearance (L/hr)</span></td>
<td class="Botrule Rrule" align="center" valign="top">6.2 ± 2.1 (24)
</td>
<td class="Botrule Rrule" align="center" valign="top">7.1 ± 2.7 (18)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Renal clearance (L/hr)</span></td>
<td class="Botrule Rrule" align="center" valign="top">5.6 ± 1.9 (5)
</td>
<td class="Botrule Rrule" align="center" valign="top">6.4 ± 2.5 (13)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">CSF: plasma ratio</span></td>
<td class="Botrule Rrule" align="center" valign="top">0.69 ± 0.19 (9) †
</td>
<td class="Botrule Rrule" align="center" valign="top">0.66 ± 0.11(5) ‡
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-3.2"></a><p></p>
<h2>Distribution
</h2>
<p class="First"><span class="Italics">In vitro</span> studies have shown that 14 – 17% of foscarnet is protein bound at plasma drug concentrations of 1 – 1000 μM.</p>
<p>The foscarnet terminal half-life determined by urinary excretion was 87.5 ± 41.8 hours, possibly due to release of foscarnet from bone. Postmortem data on several patients in European clinical trials provide evidence that foscarnet does accumulate in bone in humans; however, the extent to which this occurs has not been determined.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-3.3"></a><p></p>
<h2>Special Populations
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-3.3.1"></a><p></p>
<p class="First"><span class="Italics">Adults with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span>:</span> The pharmacokinetic properties of foscarnet have been determined in a small group of adult subjects with normal and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, as summarized in <a href="#t8">Table 8</a>:
</p>
<a name="t8"></a><table width="100%">
<caption><span>TABLE 8 Pharmacokinetic Parameters (mean ± S.D.) After a Single 60 mg/kg Dose of FOSCAVIR in 4 Groups* of Adults with Varying Degrees of Renal Function
</span></caption>
<col align="left" width="20.000%">
<col align="left" width="20.000%">
<col align="left" width="20.000%">
<col align="left" width="20.000%">
<col align="left" width="20.000%">
<tfoot><tr class="First Last"><td align="left" colspan="5" valign="top"><p class="First Footnote">*Group 1 patients had normal renal function defined as a creatinine clearance (CrCl) of &gt;80 mL/min, Group 2 CrCl was 50 – 80 mL/min, Group 3 CrCl was 25 – 49 mL/min and Group 4 CrCl was 10 – 24 mL/min.
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Parameter</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Group 1<br>(N=6)</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Group 2<br>(N=6)</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Group 3<br>(N=6)</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Group 4<br>(N=4)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Creatinine clearance (mL/min)</span></td>
<td class="Botrule Rrule" align="center" valign="top">108 ± 16
</td>
<td class="Botrule Rrule" align="center" valign="top">68 ± 8
</td>
<td class="Botrule Rrule" align="center" valign="top">34 ± 9
</td>
<td class="Botrule Rrule" align="center" valign="top">20 ± 4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Foscarnet CL (mL/min/kg)</span></td>
<td class="Botrule Rrule" align="center" valign="top">2.13 ± 0.71
</td>
<td class="Botrule Rrule" align="center" valign="top">1.33 ± 0.43
</td>
<td class="Botrule Rrule" align="center" valign="top">0.46 ± 0.14
</td>
<td class="Botrule Rrule" align="center" valign="top">0.43 ± 0.26
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Foscarnet half-life (hr)</span></td>
<td class="Botrule Rrule" align="center" valign="top">1.93 ± 0.12
</td>
<td class="Botrule Rrule" align="center" valign="top">3.35 ± 0.87
</td>
<td class="Botrule Rrule" align="center" valign="top">13.0 ± 4.05
</td>
<td class="Botrule Rrule" align="center" valign="top">25.3 ± 18.7
</td>
</tr>
</tbody>
</table>
<p>Total systemic clearance (CL) of foscarnet decreased and half-life increased with diminishing renal function (as expressed by creatinine clearance). Based on these observations, it is necessary to modify the dosage of foscarnet in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see <a href="#s43">DOSAGE AND ADMINISTRATION</a>).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L6690fb79-c078-43f3-a192-9f9fa260e89a"></a><a name="section-3.3.2"></a><p></p>
<h3>Drug Interaction</h3>
<p class="First">The pharmacokinetics of foscarnet and ganciclovir were not altered in 13 patients receiving either concomitant therapy or daily alternating therapy for maintenance of CMV disease.</p>
<p>There is no clinically significant interaction with zidovudine (AZT), or probenecid.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-4"></a><p></p>
<h1>CLINICAL TRIALS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-4.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span>
</h2>
<p class="First">A prospective, randomized, controlled clinical trial (FOS-03) was conducted in 24 patients with AIDS and <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> comparing treatment with FOSCAVIR to no treatment.  Patients received induction treatment of FOSCAVIR, 60 mg/kg every 8 hours for 3 weeks, followed by maintenance treatment with 90 mg/kg/day until <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> progression (appearance of a new lesion or advancement of the border of a posterior lesion greater than 750 microns in diameter). All diagnoses and determinations of <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> progression were made from masked reading of retinal photographs. The 13 patients randomized to treatment with FOSCAVIR had a significant delay in progression of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> compared to untreated controls. Median times to <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> progression from study entry were 93 days (range 21 – &gt;364) and 22 days (range 7 – 42), respectively.
</p>
<p>In another prospective clinical trial of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> in patients with AIDS (ACTG-915), 33 patients were treated with two to three weeks of FOSCAVIR induction (60 mg/kg TID) and then randomized to either 90 mg/kg/day or 120 mg/kg/day maintenance therapy. The median times from study entry to <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> progression were not significantly different between the treatment groups, 96 (range 14 – &gt;176) days and 140 (range 16 – &gt;233) days, respectively.
</p>
<p>In study ACTG 129/FGCRT SOCA study 107 patients with newly diagnosed <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> were randomized to treatment with FOSCAVIR (induction: 60 mg/kg TID for 2 weeks; maintenance: 90 mg/kg QD) and 127 were randomized to treatment with ganciclovir (induction: 5 mg/kg BID; maintenance: 5 mg/kg QD). The median time to progression on the two drugs was similar (Fos=59 and Gcv=56 days).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-4.2"></a><p></p>
<h2>Relapsed <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span>
</h2>
<p class="First">The <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span> Retreatment Trial (ACTG 228/SOCA CRRT) was a randomized, open-label comparison of FOSCAVIR or ganciclovir monotherapy to the combination of both drugs for the treatment of persistently active or relapsed <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> in patients with AIDS. Subjects were randomized to one of the three treatments: FOSCAVIR 90 mg/kg BID induction followed by 120 mg/kg QD maintenance (Fos); ganciclovir 5 mg/kg BID induction followed by 10 mg/kg QD maintenance (Gcv); or the combination of the two drugs, consisting of continuation of the subject's current therapy and induction dosing of the other drug (as above), followed by maintenance with FOSCAVIR 90 mg/kg QD plus ganciclovir 5 mg/kg QD (Cmb). Assessment of <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> progression was performed by masked evaluation of retinal photographs. The median times to <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> progression or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were 39 days for the FOSCAVIR group, 61 days for the ganciclovir group and 105 days for the combination group. For the alternative endpoint of <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> progression (censoring on <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>), the median times were 39 days for the FOSCAVIR group, 61 days for the ganciclovir group and 132 days for the combination group. Due to censoring on <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, the latter analysis may overestimate the treatment effect. Treatment modifications due to toxicity were more common in the combination group than in the FOSCAVIR or ganciclovir monotherapy groups (see <a href="#s39">ADVERSE REACTIONS</a> section).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-4.3"></a><p></p>
<h2>Mucocutaneous Acyclovir Resistant HSV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>
</h2>
<p class="First">In a controlled trial, patients with AIDS and mucocutaneous, acyclovir-resistant HSV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> were randomized to either FOSCAVIR (N=8) at a dose of 40 mg/kg TID or vidarabine (N=6) at a dose of 15 mg/kg per day. Eleven patients were nonrandomly assigned to receive treatment with FOSCAVIR because of prior intolerance to vidarabine. Lesions in the eight patients randomized to FOSCAVIR healed after 11 to 25 days; seven of the 11 patients nonrandomly treated with FOSCAVIR healed their lesions in 10 to 30 days. Vidarabine was discontinued because of intolerance (N=4) or poor therapeutic response (N=2). In a second trial, forty AIDS patients and three bone marrow transplant recipients with mucocutaneous, acyclovir-resistant HSV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were randomized to receive FOSCAVIR at a dose of either 40 mg/kg BID or 40 mg/kg TID. Fifteen of the 43 patients had healing of their lesions in 11 to 72 days with no difference in response between the two treatment groups.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s17"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-5.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span>
</h2>
<p class="First">FOSCAVIR is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> in patients with <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immunodeficiency syndrome</span> (AIDS).  Combination therapy with FOSCAVIR and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. SAFETY AND EFFICACY OF FOSCAVIR HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">CMV INFECTIONS</span> (e.g., <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">PNEUMONITIS</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">GASTROENTERITIS</span>); CONGENITAL OR NEONATAL CMV DISEASE; OR NONIMMUNOCOMPROMISED INDIVIDUALS.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-5.2"></a><p></p>
<h2>Mucocutaneous Acyclovir Resistant HSV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>
</h2>
<p class="First">FOSCAVIR is indicated for the treatment of acyclovir-resistant mucocutaneous HSV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in immunocompromised patients.  SAFETY AND EFFICACY OF FOSCAVIR HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER HSV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span> (e.g., <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">RETINITIS</span>, <span class="product-label-link" type="condition" conceptid="378143" conceptname="Encephalitis">ENCEPHALITIS</span>); CONGENITAL OR NEONATAL HSV DISEASE; OR HSV IN NONIMMUNOCOMPROMISED INDIVIDUALS.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s20"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First">FOSCAVIR is contraindicated in patients with clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to foscarnet sodium.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s21"></a><a name="section-7"></a><p></p>
<h1>WARNINGS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-7.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">THE MAJOR TOXICITY OF FOSCAVIR IS <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">RENAL IMPAIRMENT</span> (see <a href="#s39">ADVERSE REACTIONS</a> section). <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> is most likely to become clinically evident during the second week of induction therapy, but may occur at any time during FOSCAVIR treatment. Renal function should be monitored carefully during both induction and maintenance therapy (see <a href="#s53">PATIENT MONITORING</a> section). Elevations in serum creatinine are usually, but not always, reversible following discontinuation or dose adjustment of FOSCAVIR. Safety and efficacy data for patients with baseline serum creatinine levels greater than 2.8 mg/dL or measured 24-hour creatinine clearances &lt;50 mL/min are limited.
</p>
<p>SINCE FOSCAVIR HAS THE POTENTIAL TO CAUSE <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">RENAL IMPAIRMENT</span>, DOSE ADJUSTMENT BASED ON SERUM CREATININE IS NECESSARY. Hydration may reduce the risk of <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>. It is recommended that 750–1000 mL of normal saline or 5% dextrose solution should be given prior to the first infusion of FOSCAVIR to establish <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>. With subsequent infusions, 750–1000 mL of hydration fluid should be given with 90-120 mg/kg of FOSCAVIR, and 500 mL with 40–60 mg/kg of FOSCAVIR. Hydration fluid may need to be decreased if clinically warranted.
</p>
<p>After the first dose, the hydration fluid should be administered concurrently with each infusion of FOSCAVIR.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-7.2"></a><p></p>
<h2>Mineral and Electrolyte Abnormalities
</h2>
<p class="First">FOSCAVIR has been associated with changes in serum electrolytes including <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>, <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (see <a href="#s39">ADVERSE REACTIONS</a> section). FOSCAVIR may also be associated with a dose-related decrease in ionized serum calcium which may not be reflected in total serum calcium. This effect is likely to be related to chelation of divalent metal ions such as calcium by foscarnet. Patients should be advised to report symptoms of low <span class="product-label-link" type="condition" conceptid="4125860" conceptname="Calcium electrolyte">ionized calcium</span> such as <span class="product-label-link" type="condition" conceptid="4015676" conceptname="Circumoral paresthesia">perioral tingling</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> in the extremities and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>. Particular caution and careful management of serum electrolytes is advised in patients with altered calcium or other electrolyte levels before treatment and especially in those with neurologic or cardiac abnormalities and those receiving other drugs known to influence minerals and electrolytes (see <a href="#s53">PATIENT MONITORING</a> and <a href="#s32">Drug Interactions sections</a>). Physicians should be prepared to treat these abnormalities and their sequelae such as <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or cardiac disturbances. The rate of FOSCAVIR infusion may also affect the decrease in <span class="product-label-link" type="condition" conceptid="4125860" conceptname="Calcium electrolyte">ionized calcium</span>. <span class="Bold">Therefore, an infusion pump must be used for administration to prevent rapid intravenous infusion (see <a href="#s43">DOSAGE AND ADMINISTRATION</a> section).</span> Slowing the infusion rate may decrease or prevent symptoms.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-7.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> related to mineral and electrolyte abnormalities have been associated with FOSCAVIR treatment (see <a href="#s23">WARNING section; Mineral and Electrolyte Abnormalities</a>). Several cases of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> were associated with <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Risk factors associated with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> included impaired baseline renal function, low total serum calcium, and underlying CNS conditions.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s25"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s26"></a><a name="section-8.1"></a><p></p>
<h2>General
</h2>
<p class="First">Care must be taken to infuse solutions containing FOSCAVIR only into veins with adequate blood flow to permit rapid dilution and distribution to avoid local irritation (see <a href="#s43">DOSAGE AND ADMINISTRATION</a>). Local irritation and ulcerations of penile epithelium have been reported in male patients receiving FOSCAVIR, possibly related to the presence of drug in the urine. Cases of male and female genital irritation/ulceration have been reported in patients receiving FOSCAVIR. Adequate hydration with close attention to personal hygiene may minimize the occurrence of such events.</p>
<p>Due to the sodium content of FOSCAVIR (240 micromoles (5.5 mg) of sodium per mL), avoid FOSCAVIR use when intravenous infusion of a large amount of sodium or water may not be tolerated (e.g. in patients with <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>). FOSCAVIR should also be avoided in patients on a controlled sodium diet.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-8.2"></a><p></p>
<h2>Hematopoietic System</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> has been reported in 33% of patients receiving FOSCAVIR in controlled studies. <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">Granulocytopenia</span> has been reported in 17% of patients receiving FOSCAVIR in controlled studies; however, only 1% (2/189) were terminated from these studies because of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s28"></a><a name="section-8.3"></a><p></p>
<h2>Information for Patients
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-8.3.1"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span>:</span> Patients should be advised that FOSCAVIR is not a cure for <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>, and that they may continue to experience progression of <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> during or following treatment. They should be advised to have regular ophthalmologic examinations.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-8.3.2"></a><p></p>
<p class="First"><span class="Italics">Mucocutaneous Acyclovir-Resistant HSV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>:</span> Patients should be advised that FOSCAVIR is not a cure for HSV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. While complete healing is possible, relapse occurs in most patients. Because relapse may be due to acyclovir-sensitive HSV, sensitivity testing of the viral isolate is advised. In addition, repeated treatment with FOSCAVIR has led to the development of resistance associated with poorer response. In the case of poor therapeutic response, sensitivity testing of the viral isolate also is advised.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L2ee28b72-2b22-4460-bd68-4e78cab6e239"></a><a name="section-8.3.3"></a><p></p>
<p class="First"><span class="Italics">Effects on Ability to Drive and Use Machines:</span> Adverse effects such as <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> may occur during FOSCAVIR therapy. Patients who experience <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> or other adverse reactions that could result in impairment, should be advised to avoid driving or operating machinery.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-8.3.4"></a><p></p>
<p class="First"><span class="Italics">General:</span> Patients should be informed that the major toxicities of foscarnet are <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and that dose modifications and possibly discontinuation may be required. The importance of close monitoring while on therapy must be emphasized. Patients should be advised of the importance of reporting to their physicians symptoms of <span class="product-label-link" type="condition" conceptid="4015676" conceptname="Circumoral paresthesia">perioral tingling</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> in the extremities or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> during or after infusion as possible symptoms of electrolyte abnormalities. Should such symptoms occur, the infusion of FOSCAVIR should be stopped, appropriate laboratory samples for assessment of electrolyte concentrations obtained, and a physician consulted before resuming treatment. The rate of infusion must be no more than 1 mg/kg/minute. The potential for <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> may be minimized by accompanying FOSCAVIR administration with hydration adequate to establish and maintain a <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> during dosing.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s32"></a><a name="section-8.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First"><span class="Bold">A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described. Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>; one patient died with severe <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>. Toxicity associated with concomitant use of aerosolized pentamidine has not been reported.</span> Because FOSCAVIR can reduce serum levels of <span class="product-label-link" type="condition" conceptid="4125860" conceptname="Calcium electrolyte">ionized calcium</span>, extreme caution is advised when used concurrently with other drugs known to influence serum calcium levels (e.g., intravenous pentamidine). <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> and symptomatic <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> have been observed during concurrent treatment with FOSCAVIR and intravenous pentamidine.</p>
<p>Because of foscarnet's tendency to cause <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B, cyclosporine, acyclovir, methotrexate, tacrolimus and intravenous pentamidine (see above) unless the potential benefits outweigh the risks to the patient.</p>
<p>When diuretics are indicated, thiazides are recommended over loop diuretics because the latter inhibit renal tubular secretion, and may impair elimination of FOSCAVIR, potentially leading to toxicity.</p>
<p>Abnormal renal function has been observed in clinical practice during the use of FOSCAVIR and ritonavir, or FOSCAVIR, ritonavir, and saquinavir. (See <a href="#s43">DOSAGE and ADMINISTRATION.</a>)</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s34"></a><a name="section-8.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Carcinogenicity studies were conducted in rats and mice at oral doses of 500 mg/kg/day and 250 mg/kg/day. Oral bioavailability in unfasted rodents is &lt; 20%. No evidence of oncogenicity was reported at plasma drug levels equal to 1/3 and 1/5, respectively, of those in humans (at the maximum recommended human daily dose) as measured by the area-under-the-time/concentration curve (AUC).</p>
<p>FOSCAVIR showed genotoxic effects in the BALB/3T3 <span class="Italics">in vitro</span> transformation assay at concentrations greater than 0.5 mcg/mL and an increased frequency of chromosome aberrations in the sister chromatid exchange assay at 1000 mcg/mL. A high dose of foscarnet (350 mg/kg) caused an increase in micronucleated polychromatic erythrocytes <span class="Italics">in vivo</span> in mice at doses that produced exposures (area under curve) comparable to that anticipated clinically.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s35"></a><a name="section-8.6"></a><p></p>
<h2>Pregnancy
</h2>
<p class="First"><span class="Italics">Pregnancy, Category C:</span> There are no adequate and well-controlled studies of FOSCAVIR in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
<p><span class="Italics">Animal Data:</span> FOSCAVIR did not adversely affect fertility and general reproductive performance in rats. The results of peri- and post-natal studies in rats were also negative. However, these studies used exposures that are inadequate to define the potential for impairment of fertility at human drug exposure levels.</p>
<p>Daily subcutaneous doses up to 75 mg/kg administered to female rats prior to and during mating, during gestation, and 21 days post-partum caused a slight increase (&lt; 5%) in the number of skeletal anomalies compared with the control group. Daily subcutaneous doses up to 75 mg/kg administered to rabbits and 150 mg/kg administered to rats during gestation caused an increase in the frequency of skeletal anomalies/variations. On the basis of estimated drug exposure (as measured by AUC), the 150 mg/kg dose in rats and 75 mg/kg dose in rabbits were approximately one-eighth (rat) and one-third (rabbit) the estimated maximal daily human exposure. These studies are inadequate to define the potential <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> at levels to which women will be exposed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s36"></a><a name="section-8.7"></a><p></p>
<h2>Nursing Mothers
</h2>
<p class="First">It is not known whether FOSCAVIR is excreted in human milk; however, in lactating rats administered 75 mg/kg, FOSCAVIR was excreted in maternal milk at concentrations three times higher than peak maternal blood concentrations. Because of the potential for serious adverse events in nursing infants, a decision should be made whether to discontinue nursing or discontinue drug, taking into consideration the importance of the drug to the mother. The Centers for Disease Control and Prevention recommend that HIV-infected mothers not breast-feed their infants to avoid risking postnatal transmission of HIV.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s37"></a><a name="section-8.8"></a><p></p>
<h2>Pediatric Use
</h2>
<p class="First">The safety and effectiveness of FOSCAVIR in pediatric patients have not been established.  FOSCAVIR is deposited in teeth and bone and deposition is greater in young and growing animals.  FOSCAVIR has been demonstrated to adversely affect development of tooth enamel in mice and rats. The effects of this deposition on skeletal development have not been studied. Since deposition in human bone has also been shown to occur, it is likely that it does so to a greater degree in developing bone in pediatric patients. Administration to pediatric patients should be undertaken only after careful evaluation and only if the potential benefits for treatment outweigh the risks.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s38"></a><a name="section-8.9"></a><p></p>
<h2>Geriatric Use
</h2>
<p class="First">No studies of the efficacy or safety of FOSCAVIR in persons 65 years of age or older have been conducted. However, FOSCAVIR has been used in patients age 65 years of age and older. The pattern of adverse events seen in these patients is consistent across all age groups. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and renal function should be monitored.  (See <a href="#s43">DOSAGE AND ADMINISTRATION</a>).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s39"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<p class="First">THE MAJOR TOXICITY OF FOSCAVIR IS <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">RENAL IMPAIRMENT</span> (see <a href="#s21">WARNINGS</a> section). Approximately 33% of 189 patients with AIDS and <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> who received FOSCAVIR (60 mg/kg TID), without adequate hydration, developed significant impairment of renal function (serum creatinine ≥ 2.0 mg/dL). The incidence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> in subsequent clinical trials in which 1000 mL of normal saline or 5% dextrose solution was given with each infusion of FOSCAVIR was 12% (34/280).
</p>
<p>FOSCAVIR has been associated with changes in serum electrolytes including <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> (15-30%), <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span> (8–26%) and <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span> (6%), <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> (15–30%), and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (16–48%) (see <a href="#s21">WARNINGS</a> section). The higher percentages were derived from those patients receiving hydration.
</p>
<p>FOSCAVIR treatment was associated with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in 18/189 (10%) AIDS patients in the initial five controlled studies (see <a href="#s21">WARNINGS</a> section). Risk factors associated with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> included impaired baseline renal function, low total serum calcium, and underlying CNS conditions predisposing the patient to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. The rate of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> did not increase with duration of treatment. Three cases were associated with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of FOSCAVIR (see <a href="#s42">OVERDOSAGE</a> section).
</p>
<p>In five controlled U.S. clinical trials the most frequently reported adverse events in patients with AIDS and <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> are shown in <a href="#t9">Table 9</a>. These figures were calculated without reference to drug relationship or severity.
</p>
<a name="t9"></a><table width="100%">
<caption><span>TABLE 9 Adverse Events Reported in Five Controlled US Clinical Trials</span></caption>
<col align="left" width="22.350%">
<col align="left" width="20.725%">
<col align="left" width="36.225%">
<col align="left" width="20.700%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">n = 189</span></td>
<td class="Botrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">n = 189</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">65%
</td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Abnormal Renal Function</span></td>
<td class="Botrule Rrule" align="center" valign="top">27%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">47%
</td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">26%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">33%
</td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">26%
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">30%
</td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">10%
</td>
</tr>
</tbody>
</table>
<p>From the same controlled studies, adverse events categorized by investigator as “severe? are shown in <a href="#t10">Table 10</a>. Although <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was specifically attributed to FOSCAVIR in only one case, other complications of FOSCAVIR (i.e., <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, electrolyte abnormalities, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>) may have contributed to patient <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> (see <a href="#s21">WARNINGS</a> section).
</p>
<a name="t10"></a><table width="100%">
<caption><span>TABLE 10 Severe Adverse Events
</span></caption>
<col align="left" width="62.800%">
<col align="left" width="37.200%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">n = 189</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">14%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Abnormal Renal Function</span></td>
<td class="Botrule Rrule" align="center" valign="top">14%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">Marrow Suppression</span></td>
<td class="Botrule Rrule" align="center" valign="top">10%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">9%
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">7%
</td>
</tr>
</tbody>
</table>
<p>From the five initial U.S. controlled trials of FOSCAVIR, the following list of adverse events has been compiled regardless of causal relationship to FOSCAVIR. Evaluation of these reports was difficult because of the diverse manifestations of the underlying disease and because most patients received numerous concomitant medications.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-9.1"></a><p></p>
<h2>Incidence of 5% or Greater
</h2>
<p class="First"><span class="Italics">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>
</p>
<p><span class="Italics">Central and Peripheral Nervous System:</span> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, involuntary muscle contractions, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> including <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal seizures</span> (see <a href="#s21">WARNINGS</a>)
</p>
<p><span class="Italics">Gastrointestinal System:</span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>
</p>
<p><span class="Italics">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (see <a href="#s25">PRECAUTIONS</a>)
</p>
<p><span class="Italics">Metabolic and Nutritional:</span> mineral and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalances</span> (see <a href="#s21">WARNINGS</a>) including <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>, <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>
</p>
<p><span class="Italics">Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>
</p>
<p><span class="Italics">Respiratory System:</span> <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>
</p>
<p><span class="Italics">Skin and Appendages:</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>
</p>
<p><span class="Italics">Urinary:</span> alterations in renal function including increased serum creatinine, decreased creatinine clearance, and abnormal renal function (see <a href="#s21">WARNINGS</a>)
</p>
<p><span class="Italics">Special Senses:</span> vision abnormalities
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s41"></a><a name="section-9.2"></a><p></p>
<h2>Incidence between 1% and 5%
</h2>
<p class="First"><span class="Italics">Application Site:</span> <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site pain</span>, <span class="product-label-link" type="condition" conceptid="4319318" conceptname="Injection site inflammation">injection site inflammation</span>
</p>
<p><span class="Italics">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like symptoms, <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span>, <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>
</p>
<p><span class="Italics">Cardiovascular:</span>  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, ECG abnormalities including <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">sinus tachycardia</span>, first degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> and non-specific ST-T segment changes, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="434056" conceptname="Late effects of cerebrovascular disease">cerebrovascular disorder</span> (see <a href="#s21">WARNINGS</a>)
</p>
<p><span class="Italics">Central and Peripheral Nervous System:</span> <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">generalized spasms</span>, <span class="product-label-link" type="condition" conceptid="4311114" conceptname="Sensory disorder">sensory disturbances</span>, <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, <span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">aphasia</span>, abnormal coordination, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, EEG abnormalities (see <a href="#s21">WARNINGS</a>)
</p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4160872" conceptname="Recurrent aphthous ulcer">ulcerative stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>
</p>
<p><span class="Italics">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4332151" conceptname="Platelet disorder">platelet abnormalities</span>, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, <span class="product-label-link" type="condition" conceptid="434008" conceptname="White blood cell disorder">white blood cell abnormalities</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>
</p>
<p><span class="Italics">Liver and Biliary:</span> abnormal A-G ratio, abnormal hepatic function, increased SGPT, increased <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>
</p>
<p><span class="Italics">Metabolic and Nutritional:</span> <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, decreased weight, increased alkaline phosphatase, increased LDH, increased BUN, <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">cachexia</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> (see <a href="#s21">WARNINGS</a>)
</p>
<p><span class="Italics">Musculo-Skeletal:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>
</p>
<p><span class="Italics">Neoplasms:</span> <span class="product-label-link" type="condition" conceptid="4027114" conceptname="Pseudolymphoma">lymphoma-like disorder</span>, <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span>
</p>
<p><span class="Italics">Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive reaction</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>
</p>
<p><span class="Italics">Respiratory System:</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">respiratory disorders</span>, <span class="product-label-link" type="condition" conceptid="318459" conceptname="Respiratory insufficiency">respiratory insufficiency</span>, pulmonary infiltration, <span class="product-label-link" type="condition" conceptid="253321" conceptname="Stridor">stridor</span>, <span class="product-label-link" type="condition" conceptid="253796" conceptname="Pneumothorax">pneumothorax</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>
</p>
<p><span class="Italics">Skin and Appendages:</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulceration</span>, <span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">seborrhea</span>, erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, maculo-<span class="product-label-link" type="condition" conceptid="141094" conceptname="Lichen">papular rash</span>, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>
</p>
<p><span class="Italics">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversions</span>, eye abnormalities, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>
</p>
<p><span class="Italics">Urinary System:</span> <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="196156" conceptname="Urethral diverticulum">urethral disorder</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>
</p>
<p>Selected adverse events occurring at a rate of less than 1% in the five initial U.S. controlled clinical trials of FOSCAVIR include: syndrome of <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">inappropriate antidiuretic hormone secretion</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span>, increases in amylase and creatinine phosphokinase, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and other cardiovascular and neurologic complications.
</p>
<p>Selected adverse event data from the Foscarnet vs. Ganciclovir <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span> Trial (FGCRT), performed by the Studies of the Ocular Complications of AIDS (SOCA) Research Group, are shown in <a href="#t11">Table 11</a> (see <a href="#s13">CLINICAL TRIALS</a> section).
</p>
<a name="t11"></a><table width="100%">
<caption><span>TABLE 11 FGRCT: Selected Adverse Events*
</span></caption>
<col align="left" width="31.096%">
<col align="left" width="11.984%">
<col align="left" width="11.984%">
<col align="left" width="10.484%">
<col align="left" width="11.984%">
<col align="left" width="11.984%">
<col align="left" width="10.484%">
<tfoot>
<tr class="First"><td align="left" colspan="7" valign="top"><p class="First Footnote">* Values for the treatment groups refer only to patients who completed at least one follow-up visit – i.e., 133 to 119 patients in the ganciclovir group and 93 to 100 in the foscarnet group. “Events? denotes all events observed and “patients? the number of patients with one or more of the indicated events.
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote">†Per person-year at risk
</p></td></tr>
<tr class="Last"><td align="left" colspan="7" valign="top"><p class="First Footnote">‡Final frozen SOCA I database dated October 1991
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"><span class="Bold">EVENT</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="top"><span class="Bold">GANCICLOVIR</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="top"><span class="Bold">FOSCARNET</span></td>
</tr>
<tr>
<td class="Botrule" align="center" valign="top">No. of<br>Events
</td>
<td class="Botrule" align="center" valign="top">No. of Patients
</td>
<td class="Botrule Rrule" align="center" valign="top">Rates†
</td>
<td class="Botrule" align="center" valign="top">No. of<br>Events
</td>
<td class="Botrule" align="center" valign="top">No. of Patients
</td>
<td class="Botrule Rrule" align="center" valign="top">Rates†
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Absolute neutrophil count decreasing to &lt;0.50 x 10<span class="Sup">9</span> per liter
</td>
<td align="center" valign="top">63
</td>
<td align="center" valign="top">41
</td>
<td class="Rrule" align="center" valign="top">1.30
</td>
<td align="center" valign="top">31
</td>
<td align="center" valign="top">17
</td>
<td class="Rrule" align="center" valign="top">0.72
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Serum creatinine increasing to &gt;260 μmol per liter (&gt;2.9 mg/dL)
</td>
<td align="center" valign="top">6
</td>
<td align="center" valign="top">4
</td>
<td class="Rrule" align="center" valign="top">0.12
</td>
<td align="center" valign="top">13
</td>
<td align="center" valign="top">9
</td>
<td class="Rrule" align="center" valign="top">0.30
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> ‡
</td>
<td align="center" valign="top">21
</td>
<td align="center" valign="top">13
</td>
<td class="Rrule" align="center" valign="top">0.37
</td>
<td align="center" valign="top">19
</td>
<td align="center" valign="top">13
</td>
<td class="Rrule" align="center" valign="top">0.37
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Catheterization-related <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>
</td>
<td align="center" valign="top">49
</td>
<td align="center" valign="top">27
</td>
<td class="Rrule" align="center" valign="top">1.26
</td>
<td align="center" valign="top">51
</td>
<td align="center" valign="top">28
</td>
<td class="Rrule" align="center" valign="top">1.46
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Hospitalization
</td>
<td class="Botrule" align="center" valign="top">209
</td>
<td class="Botrule" align="center" valign="top">91
</td>
<td class="Botrule Rrule" align="center" valign="top">4.74
</td>
<td class="Botrule" align="center" valign="top">202
</td>
<td class="Botrule" align="center" valign="top">75
</td>
<td class="Botrule Rrule" align="center" valign="top">5.03
</td>
</tr>
</tbody>
</table>
<p>Selected adverse events from ACTG Study 228 (CRRT) comparing combination therapy with FOSCAVIR or ganciclovir monotherapy are shown in <a href="#t12">Table 12</a>. The most common reason for a treatment change in patients assigned to either FOSCAVIR or ganciclovir was <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> progression. The most frequent reason for a treatment change in the combination treatment group was toxicity.
</p>
<a name="t12"></a><table width="100%">
<caption><span>TABLE 12 CRRT: Selected Adverse Events
</span></caption>
<col align="left" width="29.311%">
<col align="left" width="8.537%">
<col align="left" width="7.168%">
<col align="left" width="7.858%">
<col align="left" width="8.517%">
<col align="left" width="7.188%">
<col align="left" width="7.858%">
<col align="left" width="8.497%">
<col align="left" width="7.208%">
<col align="left" width="7.858%">
<tfoot><tr class="First Last"><td align="left" colspan="10" valign="top"><p class="First Footnote">* Pts. = patients with event; †Rate = events/person/year; ‡ANC = absolute neutrophil count
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="top">Foscavir<br>N=88
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="top">Ganciclovir<br>N=93
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="top">Combination<br>N=93
</td>
</tr>
<tr>
<td class="Botrule" align="center" valign="top">No. Events
</td>
<td class="Botrule" align="center" valign="top">No. Pts.*
</td>
<td class="Botrule Rrule" align="center" valign="top">Rate†
</td>
<td class="Botrule" align="center" valign="top">No. Events
</td>
<td class="Botrule" align="center" valign="top">No. Pts.*
</td>
<td class="Botrule Rrule" align="center" valign="top">Rate†
</td>
<td class="Botrule" align="center" valign="top">No. Events
</td>
<td class="Botrule" align="center" valign="top">No. Pts.*
</td>
<td class="Botrule Rrule" align="center" valign="top">Rate†
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> (Hgb &lt;70g/L)
</td>
<td class="Botrule" align="center" valign="top">11
</td>
<td class="Botrule" align="center" valign="top">7
</td>
<td class="Botrule Rrule" align="center" valign="top">0.20
</td>
<td class="Botrule" align="center" valign="top">9
</td>
<td class="Botrule" align="center" valign="top">7
</td>
<td class="Botrule Rrule" align="center" valign="top">0.14
</td>
<td class="Botrule" align="center" valign="top">19
</td>
<td class="Botrule" align="center" valign="top">15
</td>
<td class="Botrule Rrule" align="center" valign="top">0.33
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Neutropenia‡<br>     ANC &lt;0.75 x 10<span class="Sup">9</span> cells/L<br>     ANC &lt;0.50 x 10<span class="Sup">9</span> cells/L
</td>
<td class="Botrule" align="center" valign="top">
<br>86<br>50
</td>
<td class="Botrule" align="center" valign="top">
<br>32<br>25
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>1.53<br>0.91
</td>
<td class="Botrule" align="center" valign="top">
<br>95<br>49
</td>
<td class="Botrule" align="center" valign="top">
<br>41<br>28
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>1.51<br>0.80
</td>
<td class="Botrule" align="center" valign="top">
<br>107<br>50
</td>
<td class="Botrule" align="center" valign="top">
<br>51<br>28
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>1.91<br>0.85
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span><br>     Platelets &lt;50 x 10<span class="Sup">9</span>/L<br>     Platelets &lt;20 x 10<span class="Sup">9</span>/L
</td>
<td class="Botrule" align="center" valign="top">
<br>28<br>1
</td>
<td class="Botrule" align="center" valign="top">
<br>14<br>1
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>0.50<br>0.01
</td>
<td class="Botrule" align="center" valign="top">
<br>19<br>6
</td>
<td class="Botrule" align="center" valign="top">
<br>8<br>2
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>0.43<br>0.05
</td>
<td class="Botrule" align="center" valign="top">
<br>40<br>7
</td>
<td class="Botrule" align="center" valign="top">
<br>15<br>6
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>0.56<br>0.18
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span><br>     Creatinine &gt;260 μmol/L (&gt;2.9 mg/dL)
</td>
<td class="Botrule" align="center" valign="top">
<br>9
</td>
<td class="Botrule" align="center" valign="top">
<br>7
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>0.15
</td>
<td class="Botrule" align="center" valign="top">
<br>10
</td>
<td class="Botrule" align="center" valign="top">
<br>7
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>0.17
</td>
<td class="Botrule" align="center" valign="top">
<br>11
</td>
<td class="Botrule" align="center" valign="top">
<br>10
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>0.20
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</td>
<td class="Botrule" align="center" valign="top">6
</td>
<td class="Botrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="top">0.17
</td>
<td class="Botrule" align="center" valign="top">7
</td>
<td class="Botrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="top">0.15
</td>
<td class="Botrule" align="center" valign="top">10
</td>
<td class="Botrule" align="center" valign="top">5
</td>
<td class="Botrule Rrule" align="center" valign="top">0.18
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Hospitalizations
</td>
<td class="Botrule" align="center" valign="top">86
</td>
<td class="Botrule" align="center" valign="top">53
</td>
<td class="Botrule Rrule" align="center" valign="top">1.86
</td>
<td class="Botrule" align="center" valign="top">111
</td>
<td class="Botrule" align="center" valign="top">59
</td>
<td class="Botrule Rrule" align="center" valign="top">2.36
</td>
<td class="Botrule" align="center" valign="top">118
</td>
<td class="Botrule" align="center" valign="top">64
</td>
<td class="Botrule Rrule" align="center" valign="top">2.36
</td>
</tr>
</tbody>
</table>
<p>Adverse events that have been reported in post-marketing surveillance include: <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>, prolongation of QT interval, <span class="product-label-link" type="condition" conceptid="4171925" conceptname="Gamma-glutamyl transferase raised">gamma GT increased</span>, <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span> (usually nephrogenic), <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">renal calculus</span>, <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulceration</span>, <span class="product-label-link" type="condition" conceptid="4070448" conceptname="Renal tubular acidosis">renal tubular acidosis</span>, <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">renal tubular necrosis</span>, crystal-induced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span> and <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">muscle disorders</span> including <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> and rare cases of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>. Cases of vesiculobullous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruptions</span> including <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, and <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> have been reported. In most cases, patients were taking other medications that have been associated with <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> or <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s42"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE
</h1>
<p class="First">In controlled clinical trials performed in the United States, overdosage with FOSCAVIR was reported in 10 out of 189 patients. All 10 patients experienced adverse events and all except one made a complete recovery. One patient died after receiving a total daily dose of 12.5 g for three days instead of the intended 10.9 g. The patient suffered a <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal seizure</span> and became <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">comatose</span>. Three days later the patient expired with the cause of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> listed as respiratory/<span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. The other nine patients received doses ranging from 1.14 times to 8 times their recommended doses with an average of 4 times their recommended doses. Overall, three patients had <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, three patients had renal function impairment, four patients had <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> either in limbs or periorally, and five patients had documented <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span> primarily involving calcium and phosphate.
</p>
<p><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> (up to 20 times the recommended dose) has been reported in post-marketing use of FOSCAVIR. Some of these post-marketing reports were relative <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> in that the dose of FOSCAVIR had not been adjusted in patients with a reduced renal function. The pattern of adverse events associated with a FOSCAVIR <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is consistent with the known adverse event profile of the drug.
</p>
<p>There is no specific antidote for FOSCAVIR <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Hemodialysis and hydration may be of benefit in reducing drug plasma levels in patients who receive an overdosage of FOSCAVIR, but the effectiveness of these interventions has not been evaluated. The patient should be observed for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>. Medical treatment should be instituted if clinically warranted.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s43"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<p class="First"><span class="Bold">CAUTION—DO NOT ADMINISTER FOSCAVIR BY RAPID OR BOLUS INTRAVENOUS INJECTION. THE TOXICITY OF FOSCAVIR MAY BE INCREASED AS A RESULT OF EXCESSIVE PLASMA LEVELS. CARE SHOULD BE TAKEN TO AVOID UNINTENTIONAL <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">OVERDOSE</span> BY CAREFULLY CONTROLLING THE RATE OF INFUSION. THEREFORE, AN INFUSION PUMP MUST BE USED. IN SPITE OF THE USE OF AN INFUSION PUMP, <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">OVERDOSES</span> HAVE OCCURRED.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-12"></a><p></p>
<h1>ADMINISTRATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="e44"></a><a name="section-12.1"></a><p></p>
<h2>Instructions for Administration and Preparation</h2>
<p class="First">FOSCAVIR is administered by controlled intravenous infusion, either by using a central venous line or by using a peripheral vein. The rate of infusion must be no more than 1 mg/kg/minute. An individualized dose of FOSCAVIR should be calculated on the basis of body weight (mg/kg), renal function, indication of use and dosing frequency (refer to DOSAGE subsection). <span class="Italics">To reduce the risk of <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>, creatinine clearance (mL/min/kg) should be calculated even if serum creatinine is within the normal range, and doses should be adjusted accordingly.</span></p>
<p>An individualized dose at the required concentration (24 mg/mL or 12 mg/mL) for the route of administration (central line or peripheral line) needs to be aseptically prepared prior to dispensing. The standard 24 mg/mL solution may be used with or without dilution when using a central venous catheter for infusion. When a peripheral vein catheter is used, the 24 mg/mL injection <span class="Bold">must be diluted</span> to a 12 mg/mL concentration with 5% dextrose in water or with a normal saline solution prior to administration to avoid local irritation of peripheral veins. Dilutions and/or removals of excess quantities should be accomplished under aseptic conditions. Solutions thus prepared should be used within 24 hours of first entry into a sealed bottle.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-12.2"></a><p></p>
<h2>Hydration
</h2>
<p class="First">Hydration may reduce the risk of <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>. Clinically dehydrated patients should have their condition corrected before initiating FOSCAVIR therapy. It is recommended that 750–1000 mL of normal saline or 5% dextrose solution should be given prior to the first infusion of FOSCAVIR to establish <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>. With subsequent infusions, 750–1000 mL of hydration fluid should be given with 90–120 mg/kg of FOSCAVIR, and 500 mL with 40– 60 mg/kg of FOSCAVIR. Hydration fluid may need to be decreased if clinically warranted. Oral rehydration with similar regimens may be considered in certain patients. After the first dose, the hydration fluid should be administered concurrently with each infusion of FOSCAVIR.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-12.3"></a><p></p>
<h2>Compatibility With Other Solutions/Drugs
</h2>
<p class="First">Other drugs and supplements can be administered to a patient receiving FOSCAVIR. However, care must be taken to ensure that FOSCAVIR is only administered with normal saline or 5% dextrose solution and that no other drug or supplement is administered concurrently via the same catheter. Foscarnet has been reported to be chemically incompatible with 30% dextrose, amphotericin B, and solutions containing calcium such as Ringer's lactate and TPN. Physical incompatibility with other IV drugs has also been reported including acyclovir sodium, ganciclovir, trimetrexate glucuronate, pentamidine isethionate, vancomycin, trimethoprim/sulfamethoxazole, diazepam, midazolam, digoxin, phenytoin, leucovorin, and proclorperazine.  Because of foscarnet's chelating properties, a precipitate can potentially occur when divalent cations are administered concurrently in the same catheter.
</p>
<p>Parenteral drug products must be inspected visually for particulate matter and discoloration prior to administration whenever the solution and container permit. Solutions that are discolored or contain particulate matter should not be used.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-12.4"></a><p></p>
<h2>Accidental Exposure
</h2>
<p class="First">Accidental skin and eye contact with foscarnet sodium solution may cause local irritation and <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span>. If accidental contact occurs, the exposed area should be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> with water.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s48"></a><a name="section-13"></a><p></p>
<h1>DOSAGE
</h1>
<p class="First"><span class="Bold">THE RECOMMENDED DOSAGE, FREQUENCY, OR INFUSION RATES SHOULD NOT BE EXCEEDED. ALL DOSES MUST BE INDIVIDUALIZED FOR PATIENTS' RENAL FUNCTION.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s49"></a><a name="section-13.1"></a><p></p>
<h2>Induction Treatment
</h2>
<p class="First">The recommended initial dose of FOSCAVIR for patients with normal renal function is:
</p>
<ul class="Disc">
<li>For <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> patients, either 90 mg/kg (1-1/2 to 2 hour infusion) every twelve hours or 60 mg/kg (minimum one hour infusion) every eight hours over 2-3 weeks depending on clinical response.
</li>
<li>For acyclovir-resistant HSV patients, 40 mg/kg (minimum one hour infusion) either every 8 or 12 hours for 2-3 weeks or until healed.
</li>
</ul>
<p>An infusion pump must be used to control the rate of infusion. Adequate hydration is recommended to establish a <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> (see <a href="#s45">Hydration for recommendation</a>), both prior to and during treatment to minimize renal toxicity (see <a href="#s21">WARNINGS</a>), provided there are no clinical contraindications.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s50"></a><a name="section-13.2"></a><p></p>
<h2>Maintenance Treatment
</h2>
<p class="First">Following induction treatment the recommended maintenance dose of FOSCAVIR for <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> is 90 mg/kg/day to 120 mg/kg/day (individualized for renal function) given as an intravenous infusion over 2 hours. Because the superiority of the 120 mg/kg/day has not been established in controlled trials, and given the likely relationship of higher plasma foscarnet levels to toxicity, it is recommended that most patients be started on maintenance treatment with a dose of 90 mg/kg/day. Escalation to 120 mg/kg/day may be considered should early reinduction be required because of <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> progression. Some patients who show excellent tolerance to FOSCAVIR may benefit from initiation of maintenance treatment at 120 mg/kg/day earlier in their treatment.
</p>
<p>An infusion pump must be used to control the rate of infusion with all doses. Again, hydration to establish <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> both prior to and during treatment is recommended to minimize renal toxicity, provided there are no clinical contraindications (see <a href="#s21">WARNINGS</a>).
</p>
<p>Patients who experience progression of <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> while receiving FOSCAVIR maintenance therapy may be retreated with the induction and maintenance regimens given above or with a combination of FOSCAVIR and ganciclovir (see <a href="#s13">CLINICAL TRIALS</a> section). <span class="Bold">Because of physical incompatibility, FOSCAVIR and ganciclovir must NOT be mixed.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-13.3"></a><p></p>
<h2>Use in Patients with Abnormal Renal Function
</h2>
<p class="First">FOSCAVIR should be used with caution in patients with abnormal renal function because reduced plasma clearance of foscarnet will result in elevated plasma levels (see <a href="#s8">CLINICAL PHARMACOLOGY</a>). In addition, FOSCAVIR has the potential to further impair renal function (see <a href="#s21">WARNINGS</a>). Safety and efficacy data for patients with baseline serum creatinine levels greater than 2.8 mg/dL or measured 24-hour creatinine clearances &lt; 50 mL/min are limited.</p>
<p>Renal function must be monitored carefully at baseline and during induction and maintenance therapy with appropriate dose adjustments for FOSCAVIR as outlined below (see <a href="#s52">Dose Adjustment</a> and <a href="#s53">PATIENT MONITORING</a>). During FOSCAVIR therapy if creatinine clearance <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> below the limits of the dosing nomograms (0.4 mL/min/kg), FOSCAVIR should be discontinued, the patient hydrated, and monitored daily until resolution of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is ensured.</p>
<p>FOSCAVIR is not recommended in patients undergoing hemodialysis because dosage guidelines have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s52"></a><a name="section-13.4"></a><p></p>
<h2>Dose Adjustment
</h2>
<p class="First">FOSCAVIR dosing must be individualized according to the patient's renal function status. Refer to <a href="#t13">Table 13</a> below for recommended doses and adjust the dose as indicated. Even patients with serum creatinine in the normal range may require dose adjustment; therefore, the dose should be calculated at baseline and frequently thereafter.
</p>
<p>To use this dosing guide, actual 24-hour creatinine clearance (mL/min) must be divided by body weight (kg), or the estimated creatinine clearance in mL/min/kg can be calculated from serum creatinine (mg/dL) using the following formula (modified Cockcroft and Gault equation):
</p>
<p>For males:     <span class="Underline">         140 – age          </span>       (x 0.85 for females) = mL/min/kg<br>                      Serum creatinine x 72
</p>
<a name="t13"></a><table width="100%">
<caption><span>TABLE 13 FOSCAVIR Dosage Guide Induction
</span></caption>
<col align="left" width="20.684%">
<col align="left" width="19.824%">
<col align="left" width="20.884%">
<col align="left" width="18.764%">
<col align="left" width="19.844%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">HSV: Equivalent to</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">CMV: Equivalent to</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="top"><span class="Bold">CrCI<br>(mL/min/kg)</span></td>
<td class="Botrule" align="center" rowspan="2" valign="top"><span class="Bold">80 mg/kg/day total<br>(40 mg/kg Q12h)</span></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top"><span class="Bold">120 mg/kg/day total <br>(40 mg/kg Q8h)</span></td>
<td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold">180 mg/kg/day total</span></td>
</tr>
<tr>
<td class="Botrule" align="center" valign="top"><span class="Bold">(60 mg/kg Q8h)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">(90 mg/kg Q12h)</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">&gt;1.4
</td>
<td class="Rrule" align="center" valign="top">40 Q12h
</td>
<td class="Rrule" align="center" valign="top">40 Q8h
</td>
<td align="center" valign="top">60 Q8h
</td>
<td class="Rrule" align="center" valign="top">90 Q12h
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">&gt;1.0 – 1.4
</td>
<td class="Rrule" align="center" valign="top">30 Q12h
</td>
<td class="Rrule" align="center" valign="top">30 Q8h
</td>
<td align="center" valign="top">45 Q8h
</td>
<td class="Rrule" align="center" valign="top">70 Q12h
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">&gt; 0.8 – 1.0
</td>
<td class="Rrule" align="center" valign="top">20 Q12h
</td>
<td class="Rrule" align="center" valign="top"><span class="Bold">35 Q12h</span></td>
<td align="center" valign="top"><span class="Bold">50 Q12h</span></td>
<td class="Rrule" align="center" valign="top">50 Q12h
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">&gt;0.6 – 0.8
</td>
<td class="Rrule" align="center" valign="top"><span class="Bold">35 Q24h</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">25 Q12h</span></td>
<td align="center" valign="top"><span class="Bold">40 Q12h</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">80 Q24h</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">&gt;0.5 – 0.6
</td>
<td class="Rrule" align="center" valign="top"><span class="Bold">25 Q24h</span></td>
<td class="Rrule" align="center" valign="top">40 Q24h
</td>
<td align="center" valign="top">60 Q24h
</td>
<td class="Rrule" align="center" valign="top"><span class="Bold">60 Q24h</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">&gt; 0.4 – 0.5
</td>
<td class="Rrule" align="center" valign="top"><span class="Bold">20 Q24h</span></td>
<td class="Rrule" align="center" valign="top">35 Q24h
</td>
<td align="center" valign="top">50 Q24h
</td>
<td class="Rrule" align="center" valign="top"><span class="Bold">50 Q24h</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">&lt;0.4
</td>
<td class="Botrule Rrule" align="center" valign="top">Not recommended
</td>
<td class="Botrule Rrule" align="center" valign="top">Not recommended
</td>
<td class="Botrule" align="center" valign="top">Not recommended
</td>
<td class="Botrule Rrule" align="center" valign="top">Not recommended
</td>
</tr>
</tbody>
</table>
<a name="t300"></a><table width="100%">
<caption><span>Maintenance
</span></caption>
<col align="left" width="33.333%">
<col align="left" width="33.333%">
<col align="left" width="33.333%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote">*&gt; means “greater than?, †≥ means “greater than or equal to?, ‡&lt; means “less than?
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">CMV: Equivalent to</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">CrCI<br>(mL/min/kg)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">90 mg/kg/day<br>(once daily)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">120 mg/kg/day<br>(once daily)</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">&gt;*1.4
</td>
<td class="Rrule" align="center" valign="top">90 Q24h
</td>
<td class="Rrule" align="center" valign="top">120 Q24h
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">&gt;*1.0 – 1.4
</td>
<td class="Rrule" align="center" valign="top">70 Q24h
</td>
<td class="Rrule" align="center" valign="top">90 Q24h
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">&gt;*0.8 – 1.0
</td>
<td class="Rrule" align="center" valign="top">50 Q24h
</td>
<td class="Rrule" align="center" valign="top">65 Q24h
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">&gt;*0.6 – 0.8
</td>
<td class="Rrule" align="center" valign="top"><span class="Bold">80 Q48h</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">105 Q48h</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">&gt;*0.5 – 0.6
</td>
<td class="Rrule" align="center" valign="top"><span class="Bold">60 Q48h</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">80 Q48h</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">≥†0.4 – 0.5
</td>
<td class="Rrule" align="center" valign="top"><span class="Bold">50 Q48h</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">65 Q48h</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">&lt;‡0.4
</td>
<td class="Botrule Rrule" align="center" valign="top">Not recommended
</td>
<td class="Botrule Rrule" align="center" valign="top">Not recommended
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s53"></a><a name="section-14"></a><p></p>
<h1>PATIENT MONITORING
</h1>
<p class="First">The majority of patients will experience some decrease in renal function due to FOSCAVIR administration. Therefore it is recommended that creatinine clearance, either measured or estimated using the modified Cockcroft and Gault equation based on serum creatinine, be determined at baseline, 2–3 times per week during induction therapy and once weekly during maintenance therapy, with FOSCAVIR dose adjusted accordingly (see <a href="#s52">Dose Adjustment</a>). More frequent monitoring may be required for some patients. It is also recommended that a 24-hour creatinine clearance be determined at baseline and periodically thereafter to ensure correct dosing (assuming verification of an adequate collection using creatinine index). FOSCAVIR should be discontinued if creatinine clearance drops below 0.4 mL/min/kg.</p>
<p>Due to FOSCAVIR's propensity to chelate divalent metal ions and alter levels of serum electrolytes, patients must be monitored closely for such changes. It is recommended that a schedule similar to that recommended for serum creatinine (see above) be used to monitor serum calcium, magnesium, potassium and phosphorus. Particular caution is advised in patients with decreased total serum calcium or other electrolyte levels before treatment, as well as in patients with neurologic or cardiac abnormalities, and in patients receiving other drugs known to influence serum calcium levels. Any clinically significant metabolic changes should be corrected. Also, patients who experience mild (e.g., perioral <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>) or severe (e.g., <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>) symptoms of electrolyte abnormalities should have serum electrolyte and mineral levels assessed as close in time to the event as possible.</p>
<p>Careful monitoring and appropriate management of electrolytes, calcium, magnesium and creatinine are of particular importance in patients with conditions that may predispose them to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (see <a href="#s21">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s54"></a><a name="section-15"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<p class="First">FOSCAVIR (foscarnet sodium) INJECTION, 24 mg/mL for intravenous infusion, is supplied in 250 mL glass bottles containing 6000 mg foscarnet sodium (24 mg/mL) as follows:</p>
<p>NDC 76310-024-25 250 mL bottles, cases of 10</p>
<p>For Single Use Only.</p>
<p>Store between 20° and 25°C (68° and 77°F) [See USP Controlled Room Temperature]. Protect from excessive heat (above 40°C) and from freezing. If refrigerated or exposed to temperatures below the freezing point, precipitation may occur. By keeping the bottle at room temperature with repeated <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span>, the precipitate can be brought into solution again.</p>
<p>FOSCAVIR INJECTION should be used only if the bottle and seal are intact, a vacuum is present, and the solution is clear and colorless.</p>
<p><img alt="Logos
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a09299d5-9c55-4cef-aed0-3a6a45532289&amp;name=fos01-0004-02.jpg"></p>
<p>Manufactured for:<br>Clinigen Healthcare Ltd., DE14 2WW, UK</p>
<p>By: Fresenius Kabi Austria GmbH, A-8055 Graz, Austria<br>Distributed by: Hospira, Inc., Lake Forest, IL 60045 USA</p>
<p>FOSCAVIR is a trademark of Clinigen Healthcare Ltd.</p>
<p><span class="Sup">©</span> Clinigen Healthcare Ltd., 2014</p>
<p>Date of revision: November 2014</p>
<p>M087953/01 US</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s55"></a><a name="section-16"></a><p></p>
<h1>
BOTTLE LABEL – PRINCIPAL DISPLAY PANEL
</h1>
<p class="First">
NDC 76310-024-25
</p>
<p><span class="Bold">
Foscavir
</span><span class="Sup">
®
</span></p>
<p>
(foscarnet sodium) injection
</p>
<p>
6000 mg/250 mL
</p>
<p><span class="Bold">
(24 mg/mL)
</span></p>
<p><span class="Bold">
For Central Intravenous Infusion Only
</span></p>
<p><span class="Bold">
Must Be Diluted for Peripheral Intravenous Infusion
</span></p>
<p><span class="Bold">
Rx only
</span></p>
<p><span class="Bold">
For Single Use Only.  Discard unused portion.
</span></p>
<p>
(Clinigen logo)
</p>
<p>
Mfd. for: Clinigen Healthcare Ltd., DE14 2WW, UK.
</p>
<p>
By: Fresenius Kabi Austria GmbH, A-8055 Graz, Austria.
</p>
<p>
Distributed by: Hospira Inc., Lake Forest, IL 60045 USA.
</p>
<p>
FOSCAVIR is a trademark of Clinigen Healthcare Ltd.
</p>
<p>
© Clinigen Healthcare Ltd. 2011
</p>
<p>
(Hospira logo)
</p>
<div class="Figure">
<a name="f03"></a><img alt="BOTTLE LABEL &amp;amp;amp;amp;amp;amp;#8211; PRINCIPAL DISPLAY PANEL
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a09299d5-9c55-4cef-aed0-3a6a45532289&amp;name=fos01-0004-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s56"></a><a name="section-17"></a><p></p>
<h1>
CARTON LABEL – PRINCIPAL DISPLAY PANEL
</h1>
<p class="First">
NDC 76310-024-25
</p>
<p><span class="Bold">
Foscavir
</span><span class="Sup">
®
</span></p>
<p>
(foscarnet sodium) injection
</p>
<p>
6000 mg/250 mL
</p>
<p><span class="Bold">
(24 mg/mL)
</span></p>
<p><span class="Bold">
For Central Intravenous Infusion Only
</span></p>
<p><span class="Bold">
Must Be Diluted for Peripheral 
</span></p>
<p><span class="Bold">
Intravenous Infusion
</span></p>
<p><span class="Bold">
Rx only
</span></p>
<p><span class="Bold">
For Single Use Only.  Discard unused portion.
</span></p>
<p>
(Clinigen and Hospira logos)
</p>
<p>
Mfd. for: Clinigen Healthcare Ltd., DE14 2WW, UK.
</p>
<p>
By: Fresenius Kabi Austria GmbH, A-8055 Graz, Austria.
</p>
<p>
Distributed by: Hospira Inc., Lake Forest, IL 60045 USA.
</p>
<p>
FOSCAVIR is a trademark of Clinigen Healthcare Ltd.
</p>
<p>
© Clinigen Healthcare Ltd. 2011
</p>
<p>Hospira List No.: 01182-02</p>
<p>
CA-2957
</p>
<div class="Figure">
<a name="f04"></a><img alt="CARTON LABEL &amp;amp;amp;amp;amp;amp;#8211; PRINCIPAL DISPLAY PANEL
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a09299d5-9c55-4cef-aed0-3a6a45532289&amp;name=fos01-0004-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FOSCAVIR 		
					</strong><br><span class="contentTableReg">foscarnet sodium injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:76310-024</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>foscarnet sodium</strong> (foscarnet) </td>
<td class="formItem">foscarnet sodium</td>
<td class="formItem">24 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:76310-024-25</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">250 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020068</td>
<td class="formItem">07/09/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Clinigen Healthcare Ltd.
							(856162487)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 11/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>88e208bb-8404-4a3e-91e4-e23a4fb3b4a3</div>
<div>Set id: a09299d5-9c55-4cef-aed0-3a6a45532289</div>
<div>Version: 8</div>
<div>Effective Time: 20141107</div>
</div>
</div> <div class="DistributorName">Clinigen Healthcare Ltd.</div></p>
</body></html>
